Responses to ALK Inhibitor Treatments in a Patient with Non-Small Cell Lung Cancer Harboring a Novel HPCAL1-ALK Fusion Variant: A Case Report

Responses to ALK Inhibitor Treatments in a Patient with Non-Small Cell Lung Cancer Harboring a Novel HPCAL1-ALK Fusion Variant: A Case Report

Ruixiao Wang,1,* Jiayue Qin,1,* Yafeng Fan,2 Zhimin Li,1 Chongjian Chen,1 Wenzhong Su2 1Annoroad Gene Technology Co., Ltd, Beijing 100176, People’s Republic of China; 2Department of Respiration Medicine, Shanxi Cancer Hospital, Taiyuan, Shanxi 030013, People’s Republic of China*T...

Full description

Bibliographic Details
Main Authors: Wang R, Qin J, Fan Y, Li Z, Chen C, Su W
Format: Article
Language:English
Published: Dove Medical Press 2020-05-01
Series:OncoTargets and Therapy
Subjects:
non-small cell lung cancer
anaplastic lymphoma kinase fusion
next-generation sequencing
targeted therapy
Online Access:https://www.dovepress.com/responses-to-alk-inhibitor-treatments-in-a-patient-with-non-small-cell-peer-reviewed-article-OTT

Internet

https://www.dovepress.com/responses-to-alk-inhibitor-treatments-in-a-patient-with-non-small-cell-peer-reviewed-article-OTT

Similar Items